Short answer
Teleflex Inc (TFX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Q2 2026 results for quarter ended June 30, 2026 announced August 6, 2026.
Teleflex Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 6, 2026
- Exhibit 99.1 contains GAAP financial results and management’s earnings commentary
- Non-GAAP metrics include pro forma revenue, constant-currency growth and adjusted diluted EPS
- Adjustments reflect BIOTRONIK Vascular Intervention acquisition, discontinued products and Strategic Divestitures
- Investors should compare adjusted metrics with GAAP results, given exclusions for restructuring, impairments and amortization
Item 7.01 · Regulation FD Disclosure
- Investor slide presentation tied to Teleflex’s June 30, 2026 quarterly results
- Conference call scheduled for August 6, 2026, with presentation available beforehand on the company website
- Exhibit 99.2 may provide management’s key financial and operating commentary before the earnings call
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $570.3M, up 28.9%, but adjusted constant-currency growth only 4.7%, highlighting acquisition and divestiture effects
- Adjusted EPS $1.76 versus $1.73, while GAAP EPS declined to $0.96 from $1.54 amid restructuring and transaction costs
- 2026 revenue growth outlook reduced to 13.40%-14.40%, with pro forma constant-currency growth lowered to 3.50%-4.50%
- Adjusted EPS guidance increased to $6.90-$7.20, supported by $250M Q2 repurchases and repayment of the $700M Term Loan A-2
- OEM sale generated $1.5B cash proceeds, approximately $1.25B after tax, funding debt reduction and additional shareholder returns
Item EX-99.2 · Exhibit EX-99.2
- Q2 revenue $570.3M, pro forma adjusted constant-currency growth 4.7%, led by Vascular growth of 8.0%
- Adjusted EPS $1.76, up 1.7% year over year, despite gross margin falling to 61.7% and operating margin to 19.6%
- OEM divestiture closed for approximately $1.5B proceeds, including $1.25B after tax, enabling debt reduction and shareholder returns
- Capital plan includes $800M debt reduction, $1B share repurchase authorization, and a planned $250M accelerated repurchase
- 2026 guidance mixed: adjusted EPS raised to $6.90-$7.20 while pro forma constant-currency growth cut to 3.5%-4.5%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teleflex Inc 8-K filings
Get the next TFX 8-K as it lands
Follow TFX for push alerts, or ask the research agent what this filing means.